APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tofacitinib Citrate Extended-Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Tofacitinib Citrate Extended-Release Tablets Market Analysis and Forecast 2026-2032

27 December 2025194 pages

Choose your research edition.

Industry ResearchTofacitinib Citrate Extended-Release Tablets Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Tofacitinib Citrate Extended-Release Tablets Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Tofacitinib Citrate Extended-Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tofacitinib Citrate Extended-Release Tablets Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tofacitinib Citrate Extended-Release Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tofacitinib Citrate Extended-Release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Tofacitinib Citrate Extended-Release Tablets is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Tofacitinib Citrate Extended-Release Tablets include Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lepu Pharmaceutical, Sino Therapeutics, Zydus and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Tofacitinib Citrate Extended-Release Tablets, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Tofacitinib Citrate Extended-Release Tablets, also provides the sales of main regions and countries. Of the upcoming market potential for Tofacitinib Citrate Extended-Release Tablets, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tofacitinib Citrate Extended-Release Tablets sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tofacitinib Citrate Extended-Release Tablets market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Tofacitinib Citrate Extended-Release Tablets sales, projected growth trends, production technology, application and end-user industry.

Tofacitinib Citrate Extended-Release Tablets Segment by Company

Yichang Humanwell Pharmaceutical

Sichuan Kelun Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lepu Pharmaceutical

Sino Therapeutics

Zydus

Pfizer

Tofacitinib Citrate Extended-Release Tablets Segment by Type

11mg per Tablet

22mg per Tablet

Tofacitinib Citrate Extended-Release Tablets Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Other

Tofacitinib Citrate Extended-Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib Citrate Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib Citrate Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib Citrate Extended-Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Tofacitinib Citrate Extended-Release Tablets in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tofacitinib Citrate Extended-Release Tablets sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tofacitinib Citrate Extended-Release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 11mg per Tablet Major Manufacturers Table 3. 22mg per Tablet Major Manufacturers Table 4. Global Tofacitinib Citrate Extended-Release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Rheumatoid Arthritis Major Manufacturers Table 6. Psoriatic Arthritis Major Manufacturers Table 7. Ankylosing Spondylitis Major Manufacturers Table 8. Ulcerative Colitis Major Manufacturers Table 9. Other Major Manufacturers Table 10. Tofacitinib Citrate Extended-Release Tablets Industry Trends Table 11. Tofacitinib Citrate Extended-Release Tablets Industry Drivers Table 12. Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges Table 13. Tofacitinib Citrate Extended-Release Tablets Industry Restraints Table 14. Global Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2026) Table 18. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2027-2032) Table 19. Global Tofacitinib Citrate Extended-Release Tablets Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026) & (K Units) Table 21. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2027-2032) & (K Units) Table 22. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2026) Table 23. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2027-2032) Table 24. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Tofacitinib Citrate Extended-Release Tablets Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Manufacturers (2021-2026) Table 28. Global Tofacitinib Citrate Extended-Release Tablets Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers, Product Type & Application Table 32. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Tofacitinib Citrate Extended-Release Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2026) Table 39. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2027-2032) Table 40. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 42. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 43. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2026) Table 44. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2027-2032) Table 45. Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2026) & (US$/Unit) Table 46. Global Tofacitinib Citrate Extended-Release Tablets Price by Type (2027-2032) & (US$/Unit) Table 47. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2026) Table 51. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2027-2032) Table 52. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 54. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 55. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2026) Table 56. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2027-2032) Table 57. Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2026) & (US$/Unit) Table 58. Global Tofacitinib Citrate Extended-Release Tablets Price by Application (2027-2032) & (US$/Unit) Table 59. Yichang Humanwell Pharmaceutical Company Information Table 60. Yichang Humanwell Pharmaceutical Business Overview Table 61. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 63. Yichang Humanwell Pharmaceutical Recent Development Table 64. Sichuan Kelun Pharmaceutical Company Information Table 65. Sichuan Kelun Pharmaceutical Business Overview Table 66. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 68. Sichuan Kelun Pharmaceutical Recent Development Table 69. CSPC Ouyi Pharmaceutical Company Information Table 70. CSPC Ouyi Pharmaceutical Business Overview Table 71. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 73. CSPC Ouyi Pharmaceutical Recent Development Table 74. Qilu Pharmaceutical Company Information Table 75. Qilu Pharmaceutical Business Overview Table 76. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 78. Qilu Pharmaceutical Recent Development Table 79. Lepu Pharmaceutical Company Information Table 80. Lepu Pharmaceutical Business Overview Table 81. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 83. Lepu Pharmaceutical Recent Development Table 84. Sino Therapeutics Company Information Table 85. Sino Therapeutics Business Overview Table 86. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 88. Sino Therapeutics Recent Development Table 89. Zydus Company Information Table 90. Zydus Business Overview Table 91. Zydus Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 93. Zydus Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 98. Pfizer Recent Development Table 99. North America Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 100. North America Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 101. North America Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 102. North America Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 103. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 104. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 105. North America Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 106. North America Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 107. North America Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 108. North America Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 109. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 110. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 111. North America Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 113. North America Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 114. North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 115. North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 116. North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 117. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 118. North America Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 119. United States Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 120. Canada Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 121. Mexico Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 122. Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 125. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 126. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 127. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 128. Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 129. Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 130. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 131. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 132. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 133. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 134. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 138. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 139. Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 140. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 141. Europe Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 142. Germany Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 143. France Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 144. U.K. Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 145. Italy Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 146. Russia Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 147. Spain Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 148. Netherlands Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 149. Switzerland Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 150. Sweden Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 151. Poland Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 152. China Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 153. China Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 154. China Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 155. China Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 156. China Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 157. China Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 158. China Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 159. China Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 160. China Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 161. China Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 162. China Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 163. China Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 164. Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 165. Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 166. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 167. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 168. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 169. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 170. Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 171. Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 172. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 173. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 174. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 175. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 176. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 177. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 178. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 179. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 180. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 181. Asia Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 182. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 183. Asia Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 184. Japan Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 185. South Korea Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 186. India Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 187. Australia Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 188. Taiwan Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 189. Southeast Asia Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 190. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2026) & (US$ Million) Table 191. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2027-2032) & (US$ Million) Table 192. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2026) & (K Units) Table 193. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Type (2027-2032) & (K Units) Table 194. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2021-2026) & (US$/Unit) Table 195. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Type (2027-2032) & (US$/Unit) Table 196. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2026) & (US$ Million) Table 197. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2027-2032) & (US$ Million) Table 198. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2026) & (K Units) Table 199. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Application (2027-2032) & (K Units) Table 200. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2021-2026) & (US$/Unit) Table 201. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Application (2027-2032) & (US$/Unit) Table 202. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 203. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 204. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 205. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 206. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 207. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 208. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2021-2026) & (US$/Unit) Table 209. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Price by Country (2027-2032) & (US$/Unit) Table 210. Brazil Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 211. Argentina Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 212. Chile Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 213. Colombia Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 214. Peru Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 215. Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 216. Israel Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 217. UAE Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 218. Turkey Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 219. Iran Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 220. Egypt Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Table 221. Key Raw Materials Table 222. Raw Materials Key Suppliers Table 223. Tofacitinib Citrate Extended-Release Tablets Distributors List Table 224. Tofacitinib Citrate Extended-Release Tablets Customers List Table 225. Research Programs/Design for This Report Table 226. Authors List of This Report Table 227. Secondary Sources Table 228. Primary Sources List of Figures Figure 1. Tofacitinib Citrate Extended-Release Tablets Image Figure 2. Global Tofacitinib Citrate Extended-Release Tablets Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tofacitinib Citrate Extended-Release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 4. 11mg per Tablet Image Figure 5. 22mg per Tablet Image Figure 6. Global Tofacitinib Citrate Extended-Release Tablets Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Tofacitinib Citrate Extended-Release Tablets Market Size Share 2021 VS 2025 VS 2032 Figure 8. Rheumatoid Arthritis Image Figure 9. Psoriatic Arthritis Image Figure 10. Ankylosing Spondylitis Image Figure 11. Ulcerative Colitis Image Figure 12. Other Image Figure 13. Global Tofacitinib Citrate Extended-Release Tablets Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Tofacitinib Citrate Extended-Release Tablets Revenue (2021-2032) & (US$ Million) Figure 15. Global Tofacitinib Citrate Extended-Release Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2032) Figure 18. Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032) & (K Units) Figure 19. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Tofacitinib Citrate Extended-Release Tablets Sales YoY (2021-2032) & (K Units) Figure 22. Europe Tofacitinib Citrate Extended-Release Tablets Sales YoY (2021-2032) & (K Units) Figure 23. China Tofacitinib Citrate Extended-Release Tablets Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Tofacitinib Citrate Extended-Release Tablets Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Tofacitinib Citrate Extended-Release Tablets Sales YoY (2021-2032) & (K Units) Figure 26. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032) Figure 32. Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032) Figure 35. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032) Figure 38. Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032) Figure 41. North America Tofacitinib Citrate Extended-Release Tablets Revenue Share by Type (2021-2032) Figure 42. North America Tofacitinib Citrate Extended-Release Tablets Sales Share by Type (2021-2032) Figure 43. North America Tofacitinib Citrate Extended-Release Tablets Revenue Share by Application (2021-2032) Figure 44. North America Tofacitinib Citrate Extended-Release Tablets Sales Share by Application (2021-2032) Figure 45. North America Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country (2021-2032) Figure 46. North America Tofacitinib Citrate Extended-Release Tablets Sales Share by Country (2021-2032) Figure 47. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Share by Type (2021-2032) Figure 48. Europe Tofacitinib Citrate Extended-Release Tablets Sales Share by Type (2021-2032) Figure 49. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Share by Application (2021-2032) Figure 50. Europe Tofacitinib Citrate Extended-Release Tablets Sales Share by Application (2021-2032) Figure 51. Europe Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country (2021-2032) Figure 52. Europe Tofacitinib Citrate Extended-Release Tablets Sales Share by Country (2021-2032) Figure 53. China Tofacitinib Citrate Extended-Release Tablets Revenue Share by Type (2021-2032) Figure 54. China Tofacitinib Citrate Extended-Release Tablets Sales Share by Type (2021-2032) Figure 55. China Tofacitinib Citrate Extended-Release Tablets Revenue Share by Application (2021-2032) Figure 56. China Tofacitinib Citrate Extended-Release Tablets Sales Share by Application (2021-2032) Figure 57. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Share by Type (2021-2032) Figure 58. Asia Tofacitinib Citrate Extended-Release Tablets Sales Share by Type (2021-2032) Figure 59. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Share by Application (2021-2032) Figure 60. Asia Tofacitinib Citrate Extended-Release Tablets Sales Share by Application (2021-2032) Figure 61. Asia Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country (2021-2032) Figure 62. Asia Tofacitinib Citrate Extended-Release Tablets Sales Share by Country (2021-2032) Figure 63. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Share by Type (2021-2032) Figure 64. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Share by Type (2021-2032) Figure 65. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Share by Application (2021-2032) Figure 66. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Share by Application (2021-2032) Figure 67. SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Share by Country (2021-2032) Figure 68. SAMEA Tofacitinib Citrate Extended-Release Tablets Sales Share by Country (2021-2032) Figure 69. Tofacitinib Citrate Extended-Release Tablets Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Tofacitinib Citrate Extended-Release Tablets Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • 11mg per Tablet
  • 22mg per Tablet
Applications
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Ulcerative Colitis
  • Other
Companies covered
  • Yichang Humanwell Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Lepu Pharmaceutical
  • Sino Therapeutics
  • Zydus
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Tofacitinib Citrate Extended-Release Tablets Market by Type
  3. 1.2.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 11mg per Tablet
  5. 1.2.3 22mg per Tablet
  6. 1.3 Tofacitinib Citrate Extended-Release Tablets Market by Application
  7. 1.3.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Rheumatoid Arthritis
  9. 1.3.3 Psoriatic Arthritis
  10. 1.3.4 Ankylosing Spondylitis
  11. 1.3.5 Ulcerative Colitis
  12. 1.3.6 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Tofacitinib Citrate Extended-Release Tablets Market Dynamics
  1. 2.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
  2. 2.2 Tofacitinib Citrate Extended-Release Tablets Industry Drivers
  3. 2.3 Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges
  4. 2.4 Tofacitinib Citrate Extended-Release Tablets Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region
  3. 3.2.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2021-2026)
  5. 3.2.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Region (2027-2032)
  6. 3.2.4 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region
  9. 3.4.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026)
  11. 3.4.3 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2027-2032)
  12. 3.4.4 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturers
  2. 4.1.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Manufacturers
  6. 4.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Tofacitinib Citrate Extended-Release Tablets Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers, Product Type & Application
  13. 4.7 Global Tofacitinib Citrate Extended-Release Tablets Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Tofacitinib Citrate Extended-Release Tablets Market CR5 and HHI
  16. 4.8.2 2025 Tofacitinib Citrate Extended-Release Tablets Tier 1, Tier 2, and Tier 3
5 Tofacitinib Citrate Extended-Release Tablets Market by Type
  1. 5.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type
  2. 5.1.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type
  6. 5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Type (2021-2032)
  9. 5.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Type
6 Tofacitinib Citrate Extended-Release Tablets Market by Application
  1. 6.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application
  2. 6.1.1 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Tofacitinib Citrate Extended-Release Tablets Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application
  6. 6.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Application (2021-2032)
  9. 6.3 Global Tofacitinib Citrate Extended-Release Tablets Price by Application
7 Company Profiles
  1. 7.1 Yichang Humanwell Pharmaceutical
  2. 7.1.1 Yichang Humanwell Pharmaceutical Company Information
  3. 7.1.2 Yichang Humanwell Pharmaceutical Business Overview
  4. 7.1.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  6. 7.1.5 Yichang Humanwell Pharmaceutical Recent Developments
  7. 7.2 Sichuan Kelun Pharmaceutical
  8. 7.2.1 Sichuan Kelun Pharmaceutical Company Information
  9. 7.2.2 Sichuan Kelun Pharmaceutical Business Overview
  10. 7.2.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  12. 7.2.5 Sichuan Kelun Pharmaceutical Recent Developments
  13. 7.3 CSPC Ouyi Pharmaceutical
  14. 7.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 7.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 7.3.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  18. 7.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 7.4 Qilu Pharmaceutical
  20. 7.4.1 Qilu Pharmaceutical Company Information
  21. 7.4.2 Qilu Pharmaceutical Business Overview
  22. 7.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  24. 7.4.5 Qilu Pharmaceutical Recent Developments
  25. 7.5 Lepu Pharmaceutical
  26. 7.5.1 Lepu Pharmaceutical Company Information
  27. 7.5.2 Lepu Pharmaceutical Business Overview
  28. 7.5.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  30. 7.5.5 Lepu Pharmaceutical Recent Developments
  31. 7.6 Sino Therapeutics
  32. 7.6.1 Sino Therapeutics Company Information
  33. 7.6.2 Sino Therapeutics Business Overview
  34. 7.6.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  36. 7.6.5 Sino Therapeutics Recent Developments
  37. 7.7 Zydus
  38. 7.7.1 Zydus Company Information
  39. 7.7.2 Zydus Business Overview
  40. 7.7.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  42. 7.7.5 Zydus Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
8 North America
  1. 8.1 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Type
  2. 8.1.1 North America Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  3. 8.1.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  4. 8.1.3 North America Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
  5. 8.2 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Application
  6. 8.2.1 North America Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  7. 8.2.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  8. 8.2.3 North America Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
  9. 8.3 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Country
  10. 8.3.1 North America Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Tofacitinib Citrate Extended-Release Tablets Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Type
  2. 9.1.1 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  3. 9.1.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  4. 9.1.3 Europe Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
  5. 9.2 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Application
  6. 9.2.1 Europe Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  7. 9.2.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  8. 9.2.3 Europe Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
  9. 9.3 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Country
  10. 9.3.1 Europe Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Tofacitinib Citrate Extended-Release Tablets Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Tofacitinib Citrate Extended-Release Tablets Market Size by Type
  2. 10.1.1 China Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  3. 10.1.2 China Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  4. 10.1.3 China Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
  5. 10.2 China Tofacitinib Citrate Extended-Release Tablets Market Size by Application
  6. 10.2.1 China Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  7. 10.2.2 China Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  8. 10.2.3 China Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Tofacitinib Citrate Extended-Release Tablets Market Size by Type
  2. 11.1.1 Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  3. 11.1.2 Asia Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  4. 11.1.3 Asia Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
  5. 11.2 Asia Tofacitinib Citrate Extended-Release Tablets Market Size by Application
  6. 11.2.1 Asia Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  7. 11.2.2 Asia Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  8. 11.2.3 Asia Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
  9. 11.3 Asia Tofacitinib Citrate Extended-Release Tablets Market Size by Country
  10. 11.3.1 Asia Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Tofacitinib Citrate Extended-Release Tablets Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Tofacitinib Citrate Extended-Release Tablets Market Size by Type
  2. 12.1.1 SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Tofacitinib Citrate Extended-Release Tablets Price by Type (2021-2032)
  5. 12.2 SAMEA Tofacitinib Citrate Extended-Release Tablets Market Size by Application
  6. 12.2.1 SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Tofacitinib Citrate Extended-Release Tablets Price by Application (2021-2032)
  9. 12.3 SAMEA Tofacitinib Citrate Extended-Release Tablets Market Size by Country
  10. 12.3.1 SAMEA Tofacitinib Citrate Extended-Release Tablets Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Tofacitinib Citrate Extended-Release Tablets Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Tofacitinib Citrate Extended-Release Tablets Value Chain Analysis
  2. 13.1.1 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Tofacitinib Citrate Extended-Release Tablets Production Mode & Process
  6. 13.2 Tofacitinib Citrate Extended-Release Tablets Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Tofacitinib Citrate Extended-Release Tablets Distributors
  9. 13.2.3 Tofacitinib Citrate Extended-Release Tablets Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst